Definitive chemoradiation for resectable carcinoma of the cervical esophagus: do we need more evidence?

Antoine Adenis^{1

2

3

4}, Guillaume Piessen^{3

5}, David Azria^{2

6}

Affiliations

¹ Department of Medical Oncology, Montpellier Cancer Institute (ICM), Montpellier, France.
² INSERM, Montpellier Cancer Institute (ICM), Montpellier Cancer Research Institute (IRCM), University of Montpellier, Montpellier, France.
³ FREGAT Network, Lille, France.
⁴ Lille Catholic University, Lille, France.
⁵ Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, University of Lille, Lille, France.
⁶ Department of Radiation Therapy, Montpellier Cancer Institute (ICM), Montpellier, France.

Editorial

Antoine Adenis et al. Ann Transl Med. 2017 Dec.

. 2017 Dec;5(24):503.

doi: 10.21037/atm.2017.10.27.

Antoine Adenis^{1

2

3

4}, Guillaume Piessen^{3

5}, David Azria^{2

6}

¹ Department of Medical Oncology, Montpellier Cancer Institute (ICM), Montpellier, France.
² INSERM, Montpellier Cancer Institute (ICM), Montpellier Cancer Research Institute (IRCM), University of Montpellier, Montpellier, France.
³ FREGAT Network, Lille, France.
⁴ Lille Catholic University, Lille, France.
⁵ Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, University of Lille, Lille, France.
⁶ Department of Radiation Therapy, Montpellier Cancer Institute (ICM), Montpellier, France.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus.
Zenda S, Kojima T, Kato K, Izumi S, Ozawa T, Kiyota N, Katada C, Tsushima T, Ito Y, Akimoto T, Hasegawa Y, Kanamaru M, Daiko H. Zenda S, et al. Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):976-984. doi: 10.1016/j.ijrobp.2016.08.045. Epub 2016 Sep 3. Int J Radiat Oncol Biol Phys. 2016. PMID: 27745985 Clinical Trial.

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. 10.1002/ijc.29210 - DOI - PubMed
1. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007;8:545-53. 10.1016/S1470-2045(07)70172-9 - DOI - PubMed
1. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-7. 10.1001/jama.281.17.1623 - DOI - PubMed
1. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305-14. 10.1016/S1470-2045(14)70028-2 - DOI - PubMed
1. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681-92. 10.1016/S1470-2045(11)70142-5 - DOI - PubMed